A detailed history of Rocky Mountain Advisers, LLC transactions in Novavax Inc stock. As of the latest transaction made, Rocky Mountain Advisers, LLC holds 60 shares of NVAX stock, worth $525. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60
Previous 60 -0.0%
Holding current value
$525
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$3.89 - $20.97 $4,170 - $22,479
-1,072 Reduced 94.7%
60 $0
Q1 2024

Apr 26, 2024

SELL
$3.76 - $6.02 $2,632 - $4,214
-700 Reduced 38.21%
1,132 $5,000
Q4 2023

Jan 24, 2024

BUY
$4.8 - $7.67 $6,345 - $10,139
1,322 Added 259.22%
1,832 $8,000
Q3 2023

Oct 31, 2023

BUY
$6.81 - $9.74 $3,064 - $4,383
450 Added 750.0%
510 $3,000
Q3 2020

Oct 21, 2020

BUY
$79.44 - $178.51 $4,766 - $10,710
60 New
60 $7,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $684M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Rocky Mountain Advisers, LLC Portfolio

Follow Rocky Mountain Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rocky Mountain Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rocky Mountain Advisers, LLC with notifications on news.